Ribociclib and Lumefantrine: Interaction Details

Brand names
Ribociclib
Kisqali
Dr. Brian Staiger, PharmD, BCPS

Medically reviewed by ⁠

Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
Share

Share this interaction

Lumefantrine

We don't have a separate drug information page for Lumefantrine. The FDA's drug directory lists it as part of Coartem (artemether and lumefantrine). Read the Artemether and Lumefantrine drug information page → Have a question about Lumefantrine? Ask a pharmacist, free →

What Happens When You Take Ribociclib With Lumefantrine

What can happen when they are taken together (rated Major)

Increased artemether/lumefantrine exposure and an increased risk of

Interaction Deep Dive

A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →

of artemether/lumefantrine with ribociclib should be avoided, because it may raise artemether/lumefantrine exposure and thereby heighten the risk of QT interval prolongation. Because lumefantrine has a long (3 to 6 days), caution is also warranted when other QT-prolonging agents are used after artemether/lumefantrine therapy has been completed.2

monitoring is recommended at initiation, throughout concomitant use, and whenever clinically necessary. If QTcF ( corrected by the Fridericia formula) prolongation exceeds 480 ms but is 500 ms or less, the approach depends on the setting.

In early breast cancer, ribociclib is interrupted until QTcF returns to below 480 ms, then resumed at the same dose. In advanced or metastatic breast cancer, ribociclib is interrupted until QTcF returns to below 480 ms, then resumed at the next lower dose level.

If QTcF above 480 ms recurs, ribociclib is interrupted until QTcF returns to below 480 ms, and treatment resumes at the next lower dose level. If QTcF prolongation exceeds 500 ms, ribociclib is interrupted until QTcF returns to below 480 ms, then resumed at the next lower dose level.

A recurrence of QTcF above 500 ms calls for discontinuation of ribociclib. Ribociclib should be permanently discontinued if QTcF prolongation is either above 500 ms or a change of more than 60 ms from baseline, and is accompanied by any of the following: torsade's de pointes, polymorphic ventricular , syncope, or signs/symptoms of serious . Ribociclib should also be discontinued if a dose reduction below 200 mg/day would be needed.1

The Ribociclib and Lumefantrine Interaction, Explained

Both of these medicines can affect the heart's electrical rhythm (called ). Ribociclib (Kisqali), a breast cancer medicine, may also slow the way your body clears lumefantrine, an anti-malaria medicine, so more of it could build up. Together, this may raise the chance of an irregular heartbeat. This is based on how the drugs work rather than on reported cases, but it is taken seriously.

Lumefantrine stays in the body for several days, so the effect can last after you finish the malaria treatment. Please don't stop or change either medicine on your own. Tell your pharmacist or doctor about both, and they can plan heart rhythm checks () and adjust your care as needed.

Mechanism: ribociclib inhibits , which may raise artemether/lumefantrine exposure, with (both agents prolong QT). Evidence is theoretical; onset unspecified; severity rated major.

  • Avoid where possible.
  • Lumefantrine is 3 to 6 days, so caution persists after completing therapy.
  • Monitor at initiation, during concomitant use, and as necessary.
  • QTcF >480 to ≤500 ms: interrupt ribociclib until QTcF 500 ms: interrupt until 500 ms or >60 ms above baseline with torsades, polymorphic VT, syncope, or serious signs. Discontinue if reduction below 200 mg/day is needed.

See the 2 references behind this explanation ↓

From the HelloPharmacist Pharmacy Team

AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .

How we build these pages · How we use AI · Our editorial policy

Why Ribociclib and Lumefantrine Interact

The likely mechanism

of -mediated of artemether/lumefantrine;

How Drug Interactions Work Six short figures, about a minute: how one drug can raise or lower another’s level, or add to or cancel its effect. See how it works 

How to Manage the Ribociclib and Lumefantrine Interaction

Your care team will usually try to avoid using these two together. If both are truly needed, they may monitor you more closely with heart tracings when starting, during use, and as needed. Because lumefantrine lingers for several days, this caution can continue after the malaria course ends.

  • Keep taking your medicines as prescribed unless your team tells you otherwise.
  • If your ribociclib dose needs to be paused or lowered based on ECG results, your team will individualize this.
  • Tell your pharmacist or prescriber about all medicines you take, including any malaria treatment.
  • Seek urgent help for fainting, a racing or irregular heartbeat, or severe dizziness.

Management is individual — confirm any change with your pharmacist or prescriber.

Questions for Your Pharmacist

  • Does my dose of Ribociclib or Lumefantrine need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there another option that avoids this interaction?

Ribociclib and Lumefantrine: Common Questions

How serious is the Ribociclib and Lumefantrine interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How is the Ribociclib and Lumefantrine interaction managed?

Your care team will usually try to avoid using these two together. If both are truly needed, they may monitor you more closely with heart tracings when starting, during use, and as needed. Because lumefantrine lingers for several days, this caution can continue after the malaria course ends. Keep taking your medicines as prescribed unless your team tells you otherwise. If your ribociclib dose… Management is individual — always follow your own care team's guidance.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "theoretical". Expected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.

Ask About the Ribociclib and Lumefantrine Interaction

Ask in your own words about taking Ribociclib and Lumefantrine together. The answer comes from this page’s interaction record and both drugs’ own information.

This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.

Try:

AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.

References (2)

  1. Product Information: KISQALI(R) oral tablets, ribociclib oral tablets. Novartis Pharmaceuticals Corporation (per FDA), East Hanover, NJ, 2025. DailyMed
  2. Product Information: COARTEM® oral tablets, artemether lumefantrine oral tablets. Novartis Pharmaceuticals Corporation (per DailyMed), East Hanover, NJ, 2025. DailyMed
Was this write-up helpful?

Other Serious Interactions of Ribociclib and Lumefantrine

Also serious with Lumefantrine

Also serious with Ribociclib

Still Have Questions About This Combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

About This Library

Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →

What Each Rating Means

Severity Levels

  • Contraindicated These should generally not be used together.
  • Major Potentially serious — often needs a change or close monitoring. This interaction.
  • Moderate Can be significant — usually manageable with monitoring.
  • Minor Usually limited clinical impact.

Evidence Grades

  • EstablishedWell documented — supported by controlled studies or strong clinical data.
  • ProbableGood supporting evidence, though not definitively proven.
  • SuspectedSome evidence suggests this interaction, but it is not well established.
  • PossibleLimited or conflicting evidence; the interaction may occur.
  • TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study. This interaction.

How Soon It Shows

  • RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
  • DelayedEffects tend to build up gradually over days to weeks.
  • UnspecifiedThe timing of this interaction is not well characterized. This interaction.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Back to the answer
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.